October 9, 2007
Lundbeck and anticancer applications
Analysis of:
TopoTarget and Lundbeck sign agreement forsiramesine, a new and promising mechanism in cancer therapy | www.pipelinereview.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Implications: This move conforms with Lundbeck's strategy to concentrate on CNS areas and to bring in other parties to develop non-CNS applications.
Analysis: Always with a strong CNS presence, Lundbeck divested its non-CNS activities - mostly to its Copenhagen neighbour Novo Nordisk - well over a decade ago. Lundbeck's web site shows that its aim is to become a world leader in neurology and psychiatry. The current deal conforms with this strategy.
In principle, it could make sense for Lundbeck to become involved if it proved that the technology worked in brain cancers. That would be a logical extension for the company of the indication areas it currently covers. However, there is no mention that this compound - originally tested as an anxiolytic - might be active in this area of cancer.
Analysis: Always with a strong CNS presence, Lundbeck divested its non-CNS activities - mostly to its Copenhagen neighbour Novo Nordisk - well over a decade ago. Lundbeck's web site shows that its aim is to become a world leader in neurology and psychiatry. The current deal conforms with this strategy.
In principle, it could make sense for Lundbeck to become involved if it proved that the technology worked in brain cancers. That would be a logical extension for the company of the indication areas it currently covers. However, there is no mention that this compound - originally tested as an anxiolytic - might be active in this area of cancer.
Report a Concern
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease
www.medicalnewstoday.com
Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents
jco.ascopubs.org
Healthways' Guidance Not So Healthy
www.forbes.com
Cell Genesys Ends Clinical Trials For Prostate Cancer Treatment
online.wsj.com
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
www.therapeuticsdaily.com
Azilect
September 2, 2008
Byetta Saves Lives
September 2, 2008
The Devil Is in the Details
September 1, 2008
Dangers of Methadone Usage
August 28, 2008
Healthways A Market Downturn and Results
August 26, 2008